[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"psma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:psma":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,73,89],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100643410","68ga-fapi-psma-pet-imaging-for-the-diagnosis-of-solid-tumors-100643410",false,"NCT07639801","68Ga-FAPI-PSMA PET Imaging for the Diagnosis of Solid Tumors","Evaluation of Dual-Targeted 68Ga-FAPI-PSMA PET\u002FCT for the Diagnosis and Staging of Solid Tumors","Inclusion Criteria:\n\n* Age 18-75 years\n\n  * Patients with suspected or confirmed solid tumors (e.g., prostate cancer, hepatocellular carcinoma, ovarian cancer, or endometrial cancer)\n  * Patients scheduled to undergo tumor biopsy or surgical treatment within 2 months\n  * ECOG performance status of 0 or 1\n  * Expected survival of at least 12 weeks\n  * Adequate hematologic and organ function:\n  * White blood cell count ≥ 4.0 × 10\\^9\u002FL or neutrophils ≥ 1.5 × 10\\^9\u002FL\n  * Platelet count ≥ 100 × 10\\^9\u002FL\n  * Hemoglobin ≥ 90 g\u002FL\n  * Total bilirubin ≤ 1.5 × upper limit of normal (ULN)\n  * ALT\u002FAST ≤ 2.5 × ULN (or ≤ 5 × ULN in patients with liver metastases)\n  * Creatinine ≤ 1.5 × ULN\n  * At least one measurable lesion according to RECIST 1.1 criteria\n  * Ability to understand the study procedures and willingness to sign written informed consent\n\nExclusion Criteria:\n\n* Severe hepatic or renal dysfunction\n* Inability to remain in a supine position for approximately 30 minutes during PET\u002FCT scanning\n* Refusal or inability to participate in the clinical study\n* Claustrophobia or severe psychiatric disorders that would interfere with imaging procedures\n* Any other condition that, in the investigator's judgment, would make the participant unsuitable for the study","ALL","18 Years","75 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to evaluate a novel dual-targeted PET imaging tracer, 68Ga-FAPI-PSMA, for the detection and evaluation of solid tumors. Fibroblast activation protein (FAP) and prostate-specific membrane antigen (PSMA) are two important molecular targets that are highly expressed in tumor cells or the tumor microenvironment. Combining these two targets into a single imaging probe may improve the sensitivity and accuracy of tumor detection.\n\nIn this single-center, open-label, self-controlled study, approximately 20 patients with suspected or confirmed solid tumors will undergo PET\u002FCT imaging using 68Ga-FAPI-PSMA. The imaging results will be compared with standard PET tracers such as 68Ga-PSMA-617 or 68Ga-FAPI-04. The study will assess tracer uptake in tumor lesions and compare diagnostic performance between imaging methods. The results may help determine whether 68Ga-FAPI-PSMA PET\u002FCT can improve tumor detection, staging, and clinical evaluation in patients with solid tumors.",[27,28,29,30,31,32,33],"Prostate Cancer","Hepatocellular Carcinoma","Ovarian Cancer","Solid Tumors","Endometrial Cancer","FAPI","PSMA","NOT_YET_RECRUITING","2026-06-06",{"date":37,"type":38},"2026-06-10","ACTUAL",{"date":40,"type":21},"2026-06",{"date":42,"type":21},"2026-12-31",{"name":44,"class":45},"Peking University Cancer Hospital & Institute","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":54,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":70,"locationsCount":72},"100548311","early-phase-1-99mtc-qulic-5-p1-spect-imaging-in-patients-with-prostate-cancer-100548311","NCT06419348","99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer","99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer and Compared With 68Ga-PSMA-11 PET","Inclusion Criteria:\n\n1. At least 18 years of age.\n2. Signed informed consent.\n3. Patients with suspected or newly diagnosed or previously prostate cancer, with PSMA positive expression (supporting evidence may include MRI, CT, and pathology report, etc).\n\nExclusion Criteria:\n\n1. Patients with PSMA negative expression.\n2. Patients with pregnancy.\n3. The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.\n4. Known or expected hypersensitivity to 99mTc-QULIC-5-P1 or any of its components.\n5. Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.",true,"MALE",{"count":56,"type":21},30,[58],"EARLY_PHASE1","99mTc-QULIC-5-P1 is a new radiotracer targeting PSMA, which is promising as an excellent imaging agent applicable to PSMA positive prostate cancer. This study will investigate the safety, biodistribution and potential usefulness of 99mTc-QULIC-5-P1 SPECT imaging for the diagnosis of lesions in PSMA positive prostate cancer.",[61,33,62],"Prostate Cancer Stage","SPECT","RECRUITING","2025-05-29",{"date":66,"type":38},"2025-06-04",{"date":68,"type":38},"2024-05-20",{"date":42,"type":21},{"name":71,"class":45},"First Affiliated Hospital of Chongqing Medical University",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":53,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":85,"startDateStruct":86,"completionDateStruct":87,"leadSponsor":88,"locationsCount":72},"100545858","early-phase-1-68ga-psfa-pet-imaging-in-patients-with-psmafap-positive-disease-100545858","NCT06387381","68Ga-PSFA PET Imaging in Patients With PSMA\u002FFAP Positive Disease","Inclusion Criteria:\n\n1. At least 18 years of age.\n2. Signed informed consent.\n3. Patients with suspected or newly diagnosed or previously malignant disease, with either PSMA or FAP positive expression (supporting evidence may include MRI, CT, and pathology report, etc).\n\nExclusion Criteria:\n\n1. Patients with non-malignant disease.\n2. Patients with pregnancy.\n3. The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.\n4. Known or expected hypersensitivity to 68Ga-PSFA or any of its components.\n5. Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.",{"count":56,"type":21},[58],"As a new dual receptor (PSMA and FAP) targeting PET radiotracer, 68Ga-PSFA is promising as an excellent imaging agent applicable to PSMA\u002FFAP positive diseases. In this research, we investigate the safety, biodistribution and potential usefulness of 68Ga-PSFA positron emission tomography (PET) for the diagnosis of lesions in PSMA\u002FFAP positive diseases.",[33,83,84],"FAP","Positron-Emission Tomography",{"date":66,"type":38},{"date":68,"type":38},{"date":42,"type":21},{"name":71,"class":45},{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":54,"minAge":17,"maxAge":4,"enrollmentInfo":97,"targetDuration":99,"studyType":100,"phases":4,"briefSummary":101,"conditions":102,"keywords":105,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":72},"100540698","promise-pet-registry-on-psma-pet-and-outcome-in-prostate-cancer-100540698","NCT06320223","PROMISE PET Registry on PSMA-PET and Outcome in Prostate Cancer","PROMISE Registry on Standardized Evaluation of PSMA-PET and Outcome in Prostate Cancer","PROMISE-PET","Inclusion:\n\n* Adult patients with\n* biopsy\u002Fhisto proven prostate cancer who\n* underwent PSMA PET (any type)\n* for staging or re-staging at any stage and who\n* have at least 3-year overall survival follow-up data available will be included consecutively.\n\nExclusion:\n\n* Patients with neuroendocrine prostate cancer\n* Patients with metastasized or disseminated malignancy other than prostate cancer.",{"count":98,"type":21},10000,"10 Years","OBSERVATIONAL","Background:\n\nPROMISE criteria have been defined for standardized reporting of Prostate-Specific Membrane Antigen (PSMA) PET whole-body stage of prostate cancer. PSMA PET disease extent by PROMISE has been associated with oncologic outcome.\n\nNeed:\n\nImproved prognostication across various stages of prostate cancer is needed for management guidance and study design.\n\nAim:\n\n1. To assess the prognostic value of PSMA PET\n2. To compare the prognostic value of PSMA PET with clinical prognostic scores in patients with prostate cancer at various disease stages\n\nInclusion:\n\n* Adult patients with\n* biopsy\u002Fhisto proven prostate cancer who\n* underwent PSMA PET (any type)\n* for staging or re-staging at any stage and who\n* have at least 3-year overall survival follow-up data available will be included consecutively.\n\nExclusion:\n\n* Patients with neuroendocrine prostate cancer\n* Patients with metastasized or disseminated malignancy other than prostate cancer",[27,103,104,33],"PET\u002FCT","Survivorship",[27,103,104,33,106,107,108,109],"Nuclear Medicine","Imaging","Oncology","Urology","2024-03-15",{"date":112,"type":38},"2024-03-20",{"date":114,"type":38},"2024-03-05",{"date":116,"type":21},"2035-03-05",{"name":118,"class":45},"University Hospital, Essen"]